Home :: Health :: FDA raises concerns over Valeant’s eye drop
A sign for the headquarters of Valeant Pharmaceuticals International Inc is seen in Laval, Quebec June 14, 2016. REUTERS/Christinne Muschi

FDA raises concerns over Valeant’s eye drop

Valeant Pharmaceuticals International said on Friday U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch + Lomb facility in Florida.

The U.S. Food and Drug Administration, in a complete response letter (CRL) regarding the eye drop for a type of glaucoma, raised concerns over Current Good Manufacturing Practice at the unit.

The letter did not identify any efficacy or safety issues with the eye drop, a latanoprostene bunod ophthalmic solution.

Valeant said it intends to meet the regulators and resolve these concerns, the company said in a statement.

Eye care unit Bausch + Lomb is one of Valeant’s core assets and a franchise to build on, billionaire investor and Valeant board member Bill Ackman said last week.

(Reporting by Ismail Shakil in Bengaluru; Editing by Sunil Nair)

– Reuters

Leave a Reply

Your email address will not be published. Required fields are marked *

*

x

Check Also

FSRU Project: Nakilat in strategic alliance with Höegh LNG for ‘flexible delivery’ of LNG to global market

    (TRADE NEWSWIRE): Nakilat has signed a Memorandum of Understanding (MoU) with Höegh LNG ...